Patent · US Active

PAN-ELR+ CXC chemokine antibodies for the treatment of hidradenitis suppurativa

US12037387B2 · kind B2 · utility

0Cited by

4References

22Claims

0Family size

Assignee

ELI LILLY AND COMPANY · US

Inventors

Kristine Kay Kikly · Fortville, US
Dipak R. Patel · Hatboro, US
Derrick Ryan Witcher · Fishers, US

Key dates

Filing date	Oct 15, 2019
Grant date	Jul 16, 2024
Priority date	—
Expiry date	Oct 11, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are methods and uses of antibodies against ELR+ CXC chemokines for the treatment of hidradenitis suppurativa. Also provided are doses and dosing regimens for the methods and uses of antibodies against ELR+ CXC chemokines for the treatment of hidradenitis suppurativa.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.